Repeated vitreal injection of and-vascular endothelial growth factor for incremental hard exudates in the fovea in a case of diabetic macular edema

Yusuke Sano, Shigeo Yoshida, Yuki Kubo, Yoshiyuki Kobayashi, Takahito Nakama, shintaro nakao, Toshio Hisatomi, Tatsuro Ishibashi, Kohei Sonoda

Research output: Contribution to journalArticle

Abstract

Purpose: To report a case of diabetic macular edema with incremental foveal hard exudate treated by repeated vitreal injection of aflibercept. Case: A 73-year-old male was referred to us for impaired vision in both eyes. He had been treated for diabetes mellitus in the past 20 years. Findings and Clinical Course: Corrected visual acuity was 0.3 right and 0.6 left. Central macular thickness (CMT) was 529 μm right and 339 μm left. Both eyes started treatment with vitreal injection of aflibercept. After 3 sessions, the right eye showed visual acuity of 0.6 with CMT of 314 μm. followed by slowly progressive deposit of hard exudates around the fovea. The right eye received 8 sessions of aflibercept injection during the ensuing 10 months associated with further increase of hard exudates. After a total of 17 injections during 19 months, hard exudates around the fovea disappeared with visual acuity of 0.9 and CMT of 241 μm. Visual acuity in the left eye improved to 0.9 with CMT of 263 μm after 3 sessions of treatment. Conclusion: Repeated vitreal injection of aflibercept induced improved vision and disappearance of slowly progressive hard exudates around the fovea in a case of diabetic maculopathy.

Original languageEnglish
Pages (from-to)1715-1721
Number of pages7
JournalJapanese Journal of Clinical Ophthalmology
Volume72
Issue number13
Publication statusPublished - Dec 1 2018

Fingerprint

Macular Edema
Exudates and Transudates
Vascular Endothelial Growth Factor A
Visual Acuity
Injections
Diabetes Mellitus
aflibercept
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Repeated vitreal injection of and-vascular endothelial growth factor for incremental hard exudates in the fovea in a case of diabetic macular edema. / Sano, Yusuke; Yoshida, Shigeo; Kubo, Yuki; Kobayashi, Yoshiyuki; Nakama, Takahito; nakao, shintaro; Hisatomi, Toshio; Ishibashi, Tatsuro; Sonoda, Kohei.

In: Japanese Journal of Clinical Ophthalmology, Vol. 72, No. 13, 01.12.2018, p. 1715-1721.

Research output: Contribution to journalArticle

@article{e4488a96a5af436381dbafe687830aaa,
title = "Repeated vitreal injection of and-vascular endothelial growth factor for incremental hard exudates in the fovea in a case of diabetic macular edema",
abstract = "Purpose: To report a case of diabetic macular edema with incremental foveal hard exudate treated by repeated vitreal injection of aflibercept. Case: A 73-year-old male was referred to us for impaired vision in both eyes. He had been treated for diabetes mellitus in the past 20 years. Findings and Clinical Course: Corrected visual acuity was 0.3 right and 0.6 left. Central macular thickness (CMT) was 529 μm right and 339 μm left. Both eyes started treatment with vitreal injection of aflibercept. After 3 sessions, the right eye showed visual acuity of 0.6 with CMT of 314 μm. followed by slowly progressive deposit of hard exudates around the fovea. The right eye received 8 sessions of aflibercept injection during the ensuing 10 months associated with further increase of hard exudates. After a total of 17 injections during 19 months, hard exudates around the fovea disappeared with visual acuity of 0.9 and CMT of 241 μm. Visual acuity in the left eye improved to 0.9 with CMT of 263 μm after 3 sessions of treatment. Conclusion: Repeated vitreal injection of aflibercept induced improved vision and disappearance of slowly progressive hard exudates around the fovea in a case of diabetic maculopathy.",
author = "Yusuke Sano and Shigeo Yoshida and Yuki Kubo and Yoshiyuki Kobayashi and Takahito Nakama and shintaro nakao and Toshio Hisatomi and Tatsuro Ishibashi and Kohei Sonoda",
year = "2018",
month = "12",
day = "1",
language = "English",
volume = "72",
pages = "1715--1721",
journal = "Japanese Journal of Clinical Ophthalmology",
issn = "0370-5579",
publisher = "Igaku-Shoin Ltd",
number = "13",

}

TY - JOUR

T1 - Repeated vitreal injection of and-vascular endothelial growth factor for incremental hard exudates in the fovea in a case of diabetic macular edema

AU - Sano, Yusuke

AU - Yoshida, Shigeo

AU - Kubo, Yuki

AU - Kobayashi, Yoshiyuki

AU - Nakama, Takahito

AU - nakao, shintaro

AU - Hisatomi, Toshio

AU - Ishibashi, Tatsuro

AU - Sonoda, Kohei

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Purpose: To report a case of diabetic macular edema with incremental foveal hard exudate treated by repeated vitreal injection of aflibercept. Case: A 73-year-old male was referred to us for impaired vision in both eyes. He had been treated for diabetes mellitus in the past 20 years. Findings and Clinical Course: Corrected visual acuity was 0.3 right and 0.6 left. Central macular thickness (CMT) was 529 μm right and 339 μm left. Both eyes started treatment with vitreal injection of aflibercept. After 3 sessions, the right eye showed visual acuity of 0.6 with CMT of 314 μm. followed by slowly progressive deposit of hard exudates around the fovea. The right eye received 8 sessions of aflibercept injection during the ensuing 10 months associated with further increase of hard exudates. After a total of 17 injections during 19 months, hard exudates around the fovea disappeared with visual acuity of 0.9 and CMT of 241 μm. Visual acuity in the left eye improved to 0.9 with CMT of 263 μm after 3 sessions of treatment. Conclusion: Repeated vitreal injection of aflibercept induced improved vision and disappearance of slowly progressive hard exudates around the fovea in a case of diabetic maculopathy.

AB - Purpose: To report a case of diabetic macular edema with incremental foveal hard exudate treated by repeated vitreal injection of aflibercept. Case: A 73-year-old male was referred to us for impaired vision in both eyes. He had been treated for diabetes mellitus in the past 20 years. Findings and Clinical Course: Corrected visual acuity was 0.3 right and 0.6 left. Central macular thickness (CMT) was 529 μm right and 339 μm left. Both eyes started treatment with vitreal injection of aflibercept. After 3 sessions, the right eye showed visual acuity of 0.6 with CMT of 314 μm. followed by slowly progressive deposit of hard exudates around the fovea. The right eye received 8 sessions of aflibercept injection during the ensuing 10 months associated with further increase of hard exudates. After a total of 17 injections during 19 months, hard exudates around the fovea disappeared with visual acuity of 0.9 and CMT of 241 μm. Visual acuity in the left eye improved to 0.9 with CMT of 263 μm after 3 sessions of treatment. Conclusion: Repeated vitreal injection of aflibercept induced improved vision and disappearance of slowly progressive hard exudates around the fovea in a case of diabetic maculopathy.

UR - http://www.scopus.com/inward/record.url?scp=85060980464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060980464&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85060980464

VL - 72

SP - 1715

EP - 1721

JO - Japanese Journal of Clinical Ophthalmology

JF - Japanese Journal of Clinical Ophthalmology

SN - 0370-5579

IS - 13

ER -